Word

X CHIOME

Status

Registered

Status Code

706

Status Date

Monday, February 6, 2023

Serial Number

79169641

Registration Number

5126156

Registration Date

Tuesday, January 24, 2017

Mark Type

3000

Filing Date

Tuesday, April 28, 2015

Published for Opposition

Tuesday, November 8, 2016

Trademark Owner History

Chiome Bioscience Inc. - Original Registrant

Classifications

5 Monoclonal antibodies for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; [ biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; ] medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders [ ; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; dietary supplements for humans; nutritional supplements; dietary supplements for animals; dietetic foods, namely, protein adapted for medical purposes; dietetic beverages, namely, protein-based ready to drink beverages adapted for medical purposes; food for babies; powdered milk for babies; lacteal flour for babies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]

42 Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; research and development in the field of biotechnology; ] pharmaceutical research and development [ ; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ]

The mark consists of a stylized "X" in white, within a blue square. Centered below the "X" is the term "CHIOME" in blue.
The color(s) blue and white is/are claimed as a feature of the mark.

Trademark Events

Nov 12, 2023

Partial Invalidation Processed By The Ib

Oct 11, 2023

Partial Invalidation Of Reg Ext Protection Sent To Ib

Oct 11, 2023

Invalidation Processed

Oct 6, 2023

Partial Invalidation Of Reg Ext Protection Created

Feb 6, 2023

Notice Of Acceptance Of Sec. 71 - E-Mailed

Feb 6, 2023

Registered-Sec.71 Accepted

Feb 3, 2023

Case Assigned To Post Registration Paralegal

Jan 29, 2023

Case Assigned To Post Registration Paralegal

Jan 19, 2023

Teas Section 71 Received

Jan 24, 2022

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Aug 4, 2017

Notification Of Possible Opposition - Processed By Ib

May 12, 2017

Final Decision Transaction Processed By Ib

Apr 25, 2017

Final Disposition Notice Sent To Ib

Apr 25, 2017

Final Disposition Processed

Apr 24, 2017

Final Disposition Notice Created, To Be Sent To Ib

Jan 24, 2017

Registered-Principal Register

Jan 6, 2017

Notification Of Possible Opposition - Processed By Ib

Jan 4, 2017

Notification Of Possible Opposition Sent To Ib

Jan 4, 2017

Notification Of Possible Opposition Created, To Be Sent To Ib

Nov 8, 2016

Official Gazette Publication Confirmation E-Mailed

Nov 8, 2016

Published For Opposition

Oct 19, 2016

Notification Of Possible Opposition Sent To Ib

Oct 19, 2016

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Oct 19, 2016

Notification Of Notice Of Publication E-Mailed

Oct 3, 2016

Law Office Publication Review Completed

Sep 24, 2016

Approved For Pub - Principal Register

Sep 20, 2016

Teas/Email Correspondence Entered

Sep 19, 2016

Correspondence Received In Law Office

Sep 19, 2016

Teas Response To Office Action Received

Mar 17, 2016

Notification Of Non-Final Action E-Mailed

Mar 17, 2016

Non-Final Action E-Mailed

Mar 17, 2016

Non-Final Action Written

Feb 25, 2016

Teas/Email Correspondence Entered

Feb 25, 2016

Correspondence Received In Law Office

Feb 19, 2016

Assigned To Lie

Feb 15, 2016

Teas Response To Office Action Received

Feb 15, 2016

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 15, 2016

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Sep 4, 2015

Refusal Processed By Ib

Aug 14, 2015

Non-Final Action Mailed - Refusal Sent To Ib

Aug 14, 2015

Refusal Processed By Mpu

Aug 14, 2015

Non-Final Action (Ib Refusal) Prepared For Review

Aug 13, 2015

Non-Final Action Written

Aug 11, 2015

Application Filing Receipt Mailed

Aug 8, 2015

Assigned To Examiner

Aug 6, 2015

New Application Office Supplied Data Entered

Jul 30, 2015

Sn Assigned For Sect 66a Appl From Ib